Myriad enters neuroscience with 5M Assurex Health buy

Myriad Genetics ($MYGN) is jumping into the neuroscience market with a $225 million acquisition of Assurex Health, which does genetic testing for psychotropic medicine selection. Assurex has the potential to pick up an additional $185 million if it meets certain performance-based milestones. The Assurex buy will add the Mason, OH-based company’s GeneSight genetic test to Myriad’s stable. The test uses a patient’s DNA collected via cheek swab and provides information to help healthcare providers select medications in a personalized approach. The addition will allow Myriad to join the neuroscience market, in which the U.S. spends more than $150 million in direct healthcare costs. The buy will give Myriad access to the more than 76 million people in the U.S. who have some form of mental disorder and also serves as…


Link to Full Article: Myriad enters neuroscience with 5M Assurex Health buy